Targeted Therapy in Colorectal Cancer

摘要: Despite U.S. Food and Drug Administration approval of three targeted therapeutics for colorectal cancer during the past several years, work remains in order to provide further meaningful advances. The tumor biology is well studied, with distinct pathways leading tumorigenesis: chromosomal instability pathway, mutator serrated adenoma pathway. EGFR VEGF cytokines play a prominent role development maintenance. Monoclonal antibodies targeting these have provided benefit clinic. active research, tyrosine kinase inhibitors not yet found place treatment cancer. Further research needed bridge gap between our growing knowledge agents that can clinical benefit. Combinations therapeutic modalities, which include therapy, may prove beneficial.